Epigenome Editing: Therapeutic Potential of Gene Expression Control and Challenges for Clinical Translation
Background: Regulating expression without changing DNA sequence
Epigenome editing is a technology for regulating gene expression without altering the DNA sequence. A review published in Cellular and Molecular Life Sciences summarizes advances in editor design and applications in disease models, and examines the challenges of translating the approach into therapeutics. It reviews preclinical findings from multiple studies alongside the early clinical development landscape.
Disrupted epigenetic regulation is closely linked to disease. In cancer, tumor suppressor genes may be silenced or oncogenes overexpressed; in some genetic disorders, abnormal repression of gene expression also contributes to disease. Existing epigenetic drugs inhibit relevant enzymes, but their limited ability to select specific genes and cell types can lead to off-target effects and toxicity. Could epigenome editing, which concentrates regulatory activity at specific DNA sites, help address these limitations?
Key findings: Regulatory modules and cellular context shape performance
Editors consist of a DNA-binding module and an epigenetic regulatory module. In CRISPR-based systems, guide RNA directs Cas9 with its DNA-cleaving activity disabled (dCas9) to the target. It can be coupled to DNMT3A, which induces DNA methylation, or p300, which promotes histone acetylation, to repress or activate gene expression. Designs combining multiple regulatory modules have also been developed; effects varied with both the module combination and their spatial arrangement.
The review also describes systems whose timing of activation can be controlled with light or chemicals. In a light-inducible system in HEK293T cells, ASCL1 expression reportedly increased tenfold three hours after light exposure. When the cells were then kept in the dark, ASCL1 messenger RNA (mRNA) returned to baseline within 18 hours, and light exposure induced it again. This reversibility was demonstrated in a specific cell type and system; whether the same control is possible in patient treatment remains to be tested separately.
Persistence is not determined by the editor alone. The KAL system, combining KRAB-dCas9, DNMT3A-dCas9, and DNMT3L overexpression, transiently suppressed HER2 expression in the colorectal cancer cell line HCT116, but expression had returned to baseline by day 14. In the prostate cancer cell line LNCaP, by contrast, suppression persisted. This points to the need to consider both the chromatin around the target—the structure formed by DNA and proteins—and the pre-existing epigenetic state.
Implications and outlook: Assessing delivery and safety in early clinical trials
Potential applications are expanding across monogenic disorders, cancer, neurological disorders, and chronic diseases. However, according to the review, most remain at the proof-of-concept stage. Clinical development examples include TUNE-401, a candidate for chronic hepatitis B that entered Phase 1b, and EPI-321, a candidate for facioscapulohumeral muscular dystrophy that entered Phase 1/2. Safety and tolerability are the primary endpoints in these early trials. The review also describes OTX-2002, a cancer therapy candidate that entered clinical testing, but whose developer ended its Phase 1/2 trial and temporarily paused clinical development.
To become therapeutics, editors must be delivered to the intended tissues, and changes in off-target gene expression and immune responses must be evaluated. Long-lasting changes such as DNA methylation may support long-term effects, but excessive regulation or changes in off-target cells could also pose problems. Balancing persistence and reversibility remains a question to evaluate for each target and cell type. It is also difficult to rank editors by directly comparing fold changes in expression across different studies.
Technical details and disease-specific examples are available in the full review.
Epigenome editing has emerged as a powerful platform to modulate gene expression in a precise and reversible manner. Recent advances have significantly improved the efficiency, specificity, and durability of epigenome editing systems, enabling fine-tuned transcriptional control. Building on these developments, epigenome editing platforms are now being explored for therapeutic applications. In this review, we summarize the evolution of clustered regularly interspaced short palindromic repeats (CRISPR)-based epigenome editing technologies, highlighting key improvements in effector modules. We then discuss the disease models in which epigenome editing has been applied, including monogenic disorders, cancer, neurological diseases, and chronic diseases. These examples demonstrate the broad therapeutic promise of targeted epigenetic modulation across diverse pathological contexts. Finally, we tackle key barriers to clinical translation, including cell-type and chromatin context-specific design, in vivo delivery, and multi-gene targeting for complex disease. Collectively, this review underscores the potential of epigenome editing as a versatile platform for precision medicine.
Epigenome editing may offer a way to design therapeutic candidates that raise or lower expression of disease-related genes, and serve as a research tool for testing the function of regulatory regions. Development must assess not only the magnitude of expression changes but also how long they persist and whether they can be reversed.
For example, an early clinical study of a candidate for chronic hepatitis B could be designed to assess safety and tolerability alongside epigenetic changes at the target site, target-gene expression and downstream measures, off-target effects, and immunogenicity. These are evaluation directions proposed by the review; this does not mean that assessment of these aspects has been completed. It remains to be determined whether regulatory effects seen in cells or animals can also be reproduced in patients and whether maintaining them over the long term is safe.